肌炎抗体线性免疫分析的解读中临界值至关重要
研究评估商业线性免疫分析(LIA)在健康对照、疾病对照及特发性炎症性肌病(IIM)患者中检测肌炎抗体(MAs)的性能,并探讨不同临界值对准确性的影响。新建立的MAs临界值较厂商单一临界值显著降低假阳性和多重阳性率,并使MAs对IIM或间质性肺病(ILD)的阳性预测值(PPV)从47.5%升至66.7%。作者认为应建立本地临界值并参考ANA结果,且MAs检测应作为确诊或鉴别诊断工具而非筛查工具。
要点
- 新临界值使对照组假阳性率从36.7%降至5.0%,多重阳性率从7.2%降至1.1%。
- 新临界值使MAs阳性患者队列假阳性率从45.8%降至23.8%,多重阳性率从23.7%降至15.5%。
- MAs对IIM或ILD的PPV从47.5%显著升至66.7%。
核心结论
- 建立本地临界值并交叉参考ANA结果可显著提升该检测的性能并增加解读LIA法MAs结果的信心。
- 需认识到真实世界队列中多数MAs的PPV较低,因此MAs检测应作为确诊或鉴别诊断工具而非IIM的筛查工具。
研究设计与样本
- 研究分析了MAs阳性患者(n=118)、疾病对照(DC,n=124)和健康对照(HC,n=60)的血清,使用EUROLINE Myopathies 16 Ag线性免疫分析(EUROIMMUN)检测MAs。
主要发现
- 新建立的MAs临界值较厂商单一临界值使对照组假阳性率从36.7%降至5.0%,多重阳性率从7.2%降至1.1%。
- 新临界值使MAs阳性患者队列假阳性率从45.8%降至23.8%,多重阳性率从23.7%降至15.5%。
- MAs对IIM或ILD的PPV从47.5%显著升至66.7%。
临床怎么用
- 作者认为建立本地临界值并交叉参考ANA结果可增强检测性能并提高解读MAs结果的信心。
- 作者认为应认识到真实世界队列中多数MAs的PPV较低,MAs检测应作为确诊或鉴别诊断工具而非IIM的筛查工具。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the performance of a commercial line immunoassay (LIA) in cohorts of healthy controls (HC), disease controls (DC) and patients with idiopathic inflammatory myopathies (IIMs) and investigate whether different cut-offs would enhance the accuracy of myositis antibodies (MAs) by LIA. METHODS: Sera from patients with positive MAs (n = 118), DC (n = 124) and HC (n = 60), were analysed for MAs using EUROLINE Myopathies 16 Ag LIA (EUROIMMUN). RESULTS: The newly established MAs cut-offs resulted in significantly lower both false-positive and multiple positive rates compared with the manufacturer's single cut-off, from 36.7% to 5.0% and 7.2% to 1.1% in controls, and 45.8% to 23.8% and 23.7% to 15.5% in patients with positive MAs cohorts, respectively. Furthermore, the positive predictive value (PPV) of MAs for IIMs or interstitial lung disease (ILD) increased significantly from 47.5% to 66.7%. CONCLUSION: Establishment of local cut-offs and cross-reference ANA findings can significantly enhance the assay's performance and increase the confidence in interpreting MAs results by LIA. It is important to be aware of the low PPV for most MAs in real-world cohorts; thus, the investigation of MAs should be approached as confirmatory or differential diagnosis rather than a screening tool in IIMs.
引用
- Wei X, Yun J, He J, et al. Cut-off matters in the interpretation of myositis antibodies by line immunoassay. Rheumatology (Oxford). 2025. PMID: 39951308. doi:10.1093/rheumatology/keaf101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。